var data={"title":"Cyclosporine (ciclosporin) (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cyclosporine (ciclosporin) (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/388095?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cyclosporine-ciclosporin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Cyclosporine (ciclosporin) (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=cyclosporine-ciclosporin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cyclosporine (ciclosporin) (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012536\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Only health care providers experienced in the management of systemic immunosuppressive therapy for the indicated disease should prescribe cyclosporine. At doses used in solid organ transplantation, only health care providers experienced in immunosuppressive therapy and management of organ transplant recipients should prescribe cyclosporine. Patients receiving cyclosporine should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The health care provider responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Immunosuppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Cyclosporine may increase the susceptibility to infection and the development of neoplasia. In kidney, liver, and heart transplant patients, Gengraf and Neoral may be administered with other immunosuppressive agents. Increased susceptibility to infection and the possible development of lymphoma and other neoplasms may result from the increase in the degree of immunosuppression in transplant patients.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Sandimmune and cyclosporine injection should be administered with adrenal corticosteroids but not with other immunosuppressive agents.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bioavailability:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The absorption of Sandimmune capsules and oral solution during long-term administration was found to be erratic. It is recommended that patients taking Sandimmune capsules or oral solution over a period of time be monitored at repeated intervals for cyclosporine blood levels and that subsequent dose adjustments be made to avoid toxicity from high levels and possible organ rejection from low absorption of cyclosporine. This is of special importance in liver transplants. Numerous assays are being developed to measure blood levels of cyclosporine.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Sandimmune capsules and oral solution have decreased bioavailability in comparison with Gengraf and Neoral capsules and Gengraf and Neoral oral solution. Gengraf and Neoral have increased bioavailability compared to Sandimmune capsules and oral solution and are not bioequivalent to Sandimmune and cannot be used interchangeably without the supervision of a health care provider. For a given trough concentration, cyclosporine exposure will be greater with Neoral and Gengraf than with Sandimmune. If a patient who is receiving exceptionally high doses of Sandimmune is converted to Neoral or Gengraf, particular caution should be exercised. Cyclosporine blood concentrations should be monitored in transplant and rheumatoid arthritis (RA) patients taking Gengraf and Neoral to avoid toxicity due to high concentrations. Dose adjustments should be made in transplant patients to minimize possible organ rejection due to low concentrations. Comparison of blood concentrations in the published literature with blood concentrations obtained using current assays must be done with detailed knowledge of the assay methods employed.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Psoriasis (Neoral, Gengraf):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Psoriasis patients previously treated with psoralens plus ultraviolet A (PUVA) and, to a lesser extent, methotrexate or other immunosuppressive agents, ultraviolet B (UVB), coal tar, or radiation therapy, are at an increased risk of developing skin malignancies when taking cyclosporine. Also see boxed warnings above.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypertension/nephrotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Cyclosporine, in recommended doses, can cause systemic hypertension and nephrotoxicity. The risk increases with increasing dose and duration of cyclosporine therapy. Renal dysfunction, including structural kidney damage, is a potential consequence of cyclosporine and, therefore, renal function must be monitored during therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012539\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Gengraf;</li>\n      <li>Neoral;</li>\n      <li>SandIMMUNE</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012540\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Cyclosporine;</li>\n      <li>Neoral;</li>\n      <li>Sandimmune I.V.;</li>\n      <li>Sandoz-Cyclosporine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10825673\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Immunosuppressant Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10825602\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cyclosporine-ciclosporin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Cyclosporine (ciclosporin) (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pediatric: Note: </b>Cyclosporine (modified) (Gengraf, Neoral) and cyclosporine (non-modified) (Sandimmune) are not bioequivalent and cannot be used interchangeably. Adjust initial dose to achieve desired target cyclosporine concentration; specific institutional protocols should be consulted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatitis, autoimmune (induction of remission): Note:</b> Guidelines recommend cyclosporine as second-line induction agent (AASLD [Manns 2010]; EASL 2015). Limited data available: Children &ge;2 years and Adolescents: Oral: Initial: 3 to 5 mg/kg/day divided every 8 to 12 hours; titrate to targeted cyclosporine trough concentrations; concentrations reported in the literature range between 150 to 300 ng/mL for induction of remission with lower goals (100 to 200 ng/mL) following remission. Once remission has been sustained, usually at about 6 months of therapy, cyclosporine is slowly tapered off (~14 days) and maintenance therapy with a corticosteroid &plusmn; immunosuppressant is initiated (Alvarez 1999; Cuarterolo 2006; Debray 1999; Franulovi&#263; 2012; Sciveres 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Graft versus host disease (GVHD), prevention: </b>Limited data available: Infants, Children, and Adolescents: IV followed by oral: Initial: IV: 3 to 5 mg/kg/day divided every 12 hours administered over 2 hours or as a single daily dose administered over 8 hours (Lanino 2009; Martin 2003; Storb 1986) <b>or </b>3 mg/kg/day as a continuous infusion (Nash 2000) beginning one day prior to transplant; may be given with or without methotrexate; may convert to oral therapy when tolerating oral intake; titrate dose to appropriate cyclosporine trough concentration, reported doses ranged from 6 to 12.5 mg/kg/day in divided doses every 12 hours; taper per protocol (refer to specific references for tapering and target trough details); discontinue 6 months post-transplant in the absence of acute GVHD (Lanino 2009; Martin 2003; Storb 1986). Lower doses of 1 mg/kg/day divided every 12 hours have also been reported; a study of 59 pediatric patients (median age: 8 years; range: 1 to 18 years) with acute leukemia compared low-dose IV cyclosporine (1 mg/kg/day divided every 12 hours) with standard IV dose (3 mg/kg/day divided every 12 hours); although patients receiving the lower initial IV dose experienced a higher incidence of GVHD there was a statistically significant decrease in the rate of leukemia relapse (15% vs 41% in the standard dose group) (Locatelli 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Kawasaki disease, refractory: </b>Cyclosporine (modified): Limited data available; optimal regimen not defined: Infants &ge;2 months and Children: Oral: Initial: 4 mg/kg/day divided every 12 hours, titrate to target trough concentration; maximum daily dose: 8 mg/kg/day. Dosing based on a prospective trial of 28 pediatric patients (4 months to 5 years) who failed two doses of immune globulin therapy, cyclosporine treatment was continued until patients were afebrile and CRP &lt;0.3 mg/dL or a maximum duration of 3 weeks reached (Suzuki 2011). In a case series of 10 patients (ages: 2 months to 11 years) who failed to respond to multiple therapies, some of whom received infliximab, patients received an initial loading dose of 3 mg/kg/day IV divided every 12 hours; followed by oral cyclosporine (modified) (Neoral) 10 mg/kg/day divided every 12 hours once patient was afebrile for &gt;24 hours; dose was adjusted to achieve a target concentration of 50 to 150 ng/mL; dose was tapered by 10% every 3 days over 1 month once patient was afebrile, clinically improving and had a CRP &le;1 mg/dL or after 2 weeks of therapy, whichever was longer (Tremoulet 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lupus nephritis: </b>Limited data available: Children and Adolescents: Oral: 3 to 5 mg/kg/day in divided doses for 1 to 2 years (KDIGO 2012). Reported range from trials: 2 to 5 mg/kg/day divided every 12 hours adjusted to maintain targeted trough concentrations. In one trial of 40 children and adolescents (age range: 9 to 14 years), a dosage range of 3.5 to 5 mg/kg/day was shown to effectively decrease proteinuria and allow for reduction of steroid dose; study duration 1 year (Fu 1998). A smaller trial of seven adolescents (14 to 18 years) used an initial dose of 1.5 to 3 mg/kg/day and adjusted to clinical response; after 1 year of therapy, final dosage range was 2 to 4 mg/kg/day (Baca 2006). Case reports have suggested that lower doses (1.8 to 2.5 mg/kg/day) are effective to induce remission (Kawasaki 2008; Suzuki 2006). In a small trial (n=13; age: 4 to 16 years), combination therapy with mycophenolate for induction of severe disease has been reported using cyclosporine 3 to 6 mg/kg/day in 2 to 3 divided doses (Aragon 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nephrotic syndrome: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Frequently relapsing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">BSA-based dosing: Children &ge;3 years and Adolescents: Cyclosporine (modified): Oral: 150 mg/m<sup>2</sup>/day divided twice daily; doses were titrated as necessary to achieve a target trough concentration of 80 to 100 ng/mL; dose based on a randomized, open-label, crossover study of 60 pediatric patients (age range: 3 to 18 years) (Gellermann 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-based dosing: Children and Adolescents: Oral: 4 to 5 mg/kg/day divided twice daily for at least 12 months (KDIGO 2012); doses as low as 3 mg/kg/day divided twice daily have also been recommended (Gipson 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Steroid-dependent (for steroid sparing effect): Children and Adolescents: Oral: 4 to 5 mg/kg/day divided twice daily for at least 12 months (KDIGO 2012); doses as low as 3 mg/kg/day divided twice daily have also been recommended (Gipson 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Steroid resistant:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">BSA-based dosing: Cyclosporine (modified): Children and Adolescents: Oral: 150 mg/m<sup>2</sup>/day divided twice daily; doses were titrated as necessary to achieve a target trough concentration of 120 to 180 ng/mL; if remission was not achieved by 12 weeks, doses were increased to achieve a target trough concentration of 300 to 400 ng/mL; dose based on a randomized, controlled open-label trial of 32 patients (Cyclosporine group: n=15; age: 6.99 &plusmn; 5.48 years; age range: 1.67 to 15.5 years) (Plank 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-based dosing: Cyclosporine (modified): Children and Adolescents: Oral: 5 to 6 mg/kg/day divided twice daily before meals; dose based on two randomized trials in children (Combined total n=92); target trough concentrations ranged from 100 to 250 ng/mL; lower concentrations were accepted if patients were in remission or if toxicity occurred (Choudhry 2009; Gipson 2011). Cyclosporine has been used for 6 or 12 months in trials, optimal duration has not been defined (Lombel 2013); guidelines recommend a minimum duration of 6 months; if no remission (partial or complete) is achieved after at least 6 months of therapy then discontinue; if remission is achieved (partial or complete) by 6 months then continue for a minimum of 12 months (KDIGO 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Solid organ transplantation</b>\n      <b>, rejection prophylaxis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Cyclosporine (nonmodified): <b>Note: </b>Limit parenteral use to patients unable to take capsules or oral solution; patients should be switched to an oral dosage form as soon as possible.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent IV infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer&rsquo;s labeling: Infants &ge;6 months, Children, and Adolescents: Initial: 5 to 6 mg/kg/day or one-third (<sup>1</sup>/<sub>3</sub>) of the oral dose as a single daily dose over 2 to 6 hours; administer 4 to 12 hours prior to organ transplantation or may be given postoperatively</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate dosing: Limited data available: Infants &ge;3 months, Children, and Adolescents: 2 to 6 mg/kg/day in divided doses every 8 to 12 hours (Burckart 1985; Burckart 1986b; McDiamid 1995; Tzakis 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous IV infusion: Limited data available: Children and Adolescents: 2 to 4 mg/kg/day; doses as high as 4.5 mg/kg/day have been used in patients &ge;6 years old (Al-Uzri 1994; Alvarez 2000; Benfield 2005; Clardy 1988; Kahan 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: <b>Note: </b>Dose is dependent upon type of transplant and formulation. Adjust dose to achieve desired target cyclosporine concentration; specific institutional protocols should be consulted.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Cyclosporine (nonmodified): Infants &ge;6 months, Children, and Adolescents: Initial: 10 to 14 mg/kg/day has been used for renal transplants (the manufacturer&rsquo;s labeling includes dosing from initial clinical trials of 15 mg/kg/day [range: 14 to 18 mg/kg/day]); administer 4 to 12 hours prior to organ transplantation. Continue initial dose daily for 1 to 2 weeks; taper by 5% per week to a maintenance dose of 5 to 10 mg/kg/day; some renal transplant patients may be dosed as low as 3 mg/kg/day to achieve target concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note: </b>When using nonmodified formulation, cyclosporine concentrations may increase in liver transplant patients when the T-tube is closed; may need to decrease dose (Burckart 1986b).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Cyclosporine (modified): Dose differs based on type of transplant, consult institution protocol: Dosage below is the mean (&plusmn;SD) of initial doses used in a 1994 survey.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Renal: 9 &plusmn; 3 mg/kg/day divided every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Liver: 8 &plusmn; 4 mg/kg/day divided every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Heart: 7 &plusmn; 3 mg/kg/day divided every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Conversion to cyclosporine (modified) from cyclosporine (nonmodified):</i> Start with daily dose previously used and adjust to obtain preconversion cyclosporine trough concentration. Plasma concentrations should be monitored every 4 to 7 days and dose adjusted as necessary, until desired trough concentration is obtained. When transferring patients with previously poor absorption of cyclosporine (nonmodified), monitor trough concentrations at least twice weekly (especially if initial dose exceeds 10 mg/kg daily); high plasma concentrations are likely to occur due to improved bioavailability.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Psoriasis:</b> Oral: Cyclosporine (modified): Initial: 2.5 mg/kg/day divided every 12 hours; may increase dose by 0.5 mg/kg/day if insufficient response is seen after 4 weeks of treatment; additional dosage increases may be made every 2 weeks if needed; maximum daily dose: 4 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Discontinue if no benefit is seen by 6 weeks of therapy at the maximum dose. Once patients are adequately controlled, the dose should be decreased to the lowest effective dose. Doses lower than 2.5 mg/kg daily may be effective. The Canadian labeling recommends attempting to wean patients off therapy if no relapse occurs within 6 months of achieving remission. Treatment longer than 1 year is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Increase the frequency of blood pressure monitoring after each alteration in dosage of cyclosporine. Cyclosporine dosage should be decreased by 25% to 50% in patients with no history of hypertension who develop sustained hypertension during therapy and, if hypertension persists, treatment with cyclosporine should be discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatoid arthritis:</b> Oral: Cyclosporine (modified): Initial: 2.5 mg/kg/day divided every 12 hours. Dose may increase by 0.5 to 0.75 mg/kg/day if insufficient response is seen after 8 weeks of treatment; additional dosage increases may be made again at 12 weeks; maximum daily dose: 4 mg/kg/day. Discontinue if no benefit is seen by 16 weeks of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Increase the frequency of blood pressure monitoring after each alteration in dosage of cyclosporine. Cyclosporine dosage should be decreased by 25% to 50% in patients with no history of hypertension who develop sustained hypertension during therapy and, if hypertension persists, treatment with cyclosporine should be discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Solid organ transplant (newly transplanted patients):</b> Adjunct therapy with corticosteroids is recommended. Initial dose should be given 4 to 12 hours prior to transplant or may be given postoperatively; adjust initial dose to achieve desired plasma concentration.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Dose is dependent upon type of transplant and formulation:</p>\n    <p style=\"text-indent:0em;margin-left:6em;\">Cyclosporine (modified):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Renal: 9 &plusmn; 3 mg/kg daily, in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Liver: 8 &plusmn; 4 mg/kg daily, in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Heart: 7 &plusmn; 3 mg/kg daily, in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Cyclosporine (nonmodified): Initial doses of 10 to 14 mg/kg daily have been used for renal transplants (the manufacturer&rsquo;s labeling includes dosing from initial clinical trials of 15 mg/kg daily [range: 14 to 18 mg/kg daily]; however, this higher dosing level is rarely used any longer). Continue initial dose daily for 1 to 2 weeks; taper by 5% per week to a maintenance dose of 5 to 10 mg/kg daily; some renal transplant patients may be dosed as low as 3 mg/kg daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> When using the nonmodified formulation, cyclosporine concentrations may increase in liver transplant patients when the T-tube is closed; dose may need decreased.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Cyclosporine (nonmodified): Manufacturer's labeling: Initial dose: 5 to 6 mg/kg daily or one-third (<sup>1</sup>/<sub>3</sub>) of the oral dose as a single dose, infused over 2 to 6 hours; use should be limited to patients unable to take capsules or oral solution; patients should be switched to an oral dosage form as soon as possible.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Many transplant centers administer cyclosporine as &quot;divided dose&quot; infusions (in 2 to 3 doses daily) or as a continuous (24-hour) infusion; dosages range from 3 to 7.5 mg/kg daily. Specific institutional protocols should be consulted.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note: Conversion to cyclosporine (modified) from cyclosporine (nonmodified):</b> Start with daily dose previously used and adjust to obtain preconversion cyclosporine trough concentration. Plasma concentrations should be monitored every 4 to 7 days and dose adjusted as necessary, until desired trough concentrations is obtained. When transferring patients with previously poor absorption of cyclosporine (nonmodified), monitor trough concentrations at least twice weekly (especially if initial dose exceeds 10 mg/kg daily); high plasma concentrations are likely to occur.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012692\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gengraf: 25 mg [contains cremophor el, fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gengraf: 50 mg [contains alcohol, usp, fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gengraf: 100 mg [contains cremophor el, fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neoral: 25 mg, 100 mg [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SandIMMUNE: 25 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SandIMMUNE: 50 mg/mL (5 mL) [contains alcohol, usp, cremophor el]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gengraf: 100 mg/mL (50 mL) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neoral: 100 mg/mL (50 mL) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SandIMMUNE: 100 mg/mL (50 mL) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/mL (50 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012552\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21664250\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=cyclosporine-ciclosporin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Cyclosporine (ciclosporin) (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclosporine (modified): Gengraf and Neoral</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclosporine (non-modified): SandIMMUNE</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclosporine injection contains polyoxyethylated castor oil (Cremophor EL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10825603\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer consistently with relation to time of day and meals</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral solution: Use syringe provided to measure dose. Administer with oral syringe, glass dropper, or glass container (not plastic or styrofoam cup); to improve palatability, may mix Sandimmune oral solution with milk, chocolate milk, or orange juice that is at room temperature. May mix Neoral with orange juice or apple juice that is at room temperature; avoid mixing with grapefruit juice; Neoral mixed with milk can be unpalatable; mix in a glass container, stir well and drink at once; do not allow to stand before drinking; rinse container with more diluent to ensure that the total dose is taken. After use, dry outside of dosing syringe; do not rinse with water or other cleaning agents; if dosage syringe requires cleaning it must be completely dry before resuming use; introduction of water into the product will cause dose variations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: To minimize leaching of DEHP, non-PVC containers and sets should be used for administration. May administer by IV intermittent infusion or continuous infusion; for intermittent infusion, administer over 2 to 6 hours. Anaphylaxis has been reported with IV use. Patients should be continuously monitored for at least the first 30 minutes of the infusion and should be monitored frequently thereafter.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130962\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV preparation, when compounding, double gloves, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) are recommended. Double gloving and a gown are required during IV administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012616\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsules (modified): Store in the original unit-dose container at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsules (non-modified): Store at 25&deg;C (77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). An odor may be detected upon opening the unit-dose container, which will dissipate shortly thereafter. This odor does not affect the quality of the product.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection: Store below 30&deg;C (86&deg;F) or at controlled room temperature (product dependent). Protect from light. The manufacturer recommends discarding diluted infusion solutions in D5W or NS after 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral solution (modified): Store in the original container at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Do not store in the refrigerator. Once opened, use within 2 months. At temperatures below 20&deg;C (68&deg;F), the solution may gel; light flocculation or the formation of a light sediment also may occur. There is no impact on product performance or dosing using the syringe provided. Allow to warm to room temperature (25&deg;C [77&deg;F]) to reverse these changes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral solution (non-modified): Store in the original container at temperatures below 30&deg;C (86&deg;F). Do not store in the refrigerator. Protect from freezing. Once opened, use within 2 months.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10825674\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclosporine modified (Gengraf, Neoral): Prophylaxis of organ rejection in kidney, liver, and heart transplants in combination with azathioprine and corticosteroids (FDA approved in ages &ge;1 year and adults); treatment of severe, active rheumatoid arthritis (RA) not responsive to methotrexate alone (FDA approved in adults); treatment of severe, recalcitrant plaque psoriasis in nonimmunocompromised patients unresponsive to or unable to tolerate other systemic therapy (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclosporine nonmodified (Sandimmune): Prophylaxis of organ rejection in kidney, liver, and heart transplants in combination with corticosteroids; treatment of chronic organ rejection in patients previously treated with other immunosuppressive (All indications: FDA approved in ages &ge;6 months and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Has also been used to treat nephrotic syndrome, lupus nephritis, refractory Kawasaki disease, autoimmune hepatitis, and prevention and treatment of graft-versus-host disease in bone marrow transplant patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012538\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CycloSPORINE may be confused with cyclophosphamide, Cyklokapron, cycloSERINE</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CycloSPORINE modified (Neoral, Gengraf) may be confused with cycloSPORINE non-modified (SandIMMUNE)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gengraf may be confused with Prograf</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neoral may be confused with Neurontin, Nizoral</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SandIMMUNE may be confused with SandoSTATIN</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012604\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reactions reported with systemic use, including rheumatoid arthritis, psoriasis, and transplantation (kidney, liver, and heart).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Any indication:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Edema, hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Hypertrichosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Female genital tract disease, hirsutism, increased serum triglycerides</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal distress, diarrhea, dyspepsia, gingival hyperplasia, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Increased susceptibility to infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Leg cramps, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Increased serum creatinine, renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Kidney, liver, and heart transplant only:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Chest pain, flushing, glomerular capillary thrombosis, myocardial infarction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Anxiety, confusion, convulsions, lethargy, tingling sensation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Acne vulgaris, nail disease (brittle fingernails), hair breakage, night sweats, pruritus, skin infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Gynecomastia, hyperglycemia, hypomagnesemia, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Anorexia, aphthous stomatitis, constipation, dysphagia, gastritis, hiccups, pancreatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Hematuria, urinary tract infection (kidney transplant)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, leukopenia, lymphoma, thrombocytopenia, upper gastrointestinal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Hepatotoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Abscess, cytomegalovirus disease, fungal infection (systemic), localized fungal infection, septicemia, viral infection (kidney transplant)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Conjunctivitis, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Hearing loss, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Pneumonia, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Rheumatoid arthritis only:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Abnormal heart sounds, cardiac arrhythmia, cardiac failure, chest pain, myocardial infarction, peripheral ischemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Anxiety, depression, dizziness, drowsiness, emotional lability, hypoesthesia, insomnia, lack of concentration, malaise, migraine, neuropathy, nervousness, pain, paranoia, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Cellulitis, dermatological reaction, dermatitis, diaphoresis, dyschromia, eczema, enanthema, folliculitis, nail disease, pruritus, urticaria, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Decreased libido, diabetes mellitus, goiter, hot flash, hyperkalemia, hyperuricemia, hypoglycemia, increased libido, menstrual disease, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Constipation, dysgeusia, dysphagia, enlargement of salivary glands, eructation, esophagitis, flatulence, gastric ulcer, gastritis, gastroenteritis, gingival hemorrhage, gingivitis, glossitis, peptic ulcer, tongue disease, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Breast fibroadenosis, hematuria, leukorrhea, mastalgia, nocturia, urine abnormality, urinary incontinence, urinary urgency, uterine hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, carcinoma, leukopenia, lymphadenopathy, purpura</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Hyperbilirubinemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Abscess (including renal), bacterial infection, candidiasis, fungal infection, herpes simplex infection, herpes zoster, viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, bone fracture, dislocation, myalgia, stiffness, synovial cyst, tendon disease, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Cataract, conjunctivitis, eye pain, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Tinnitus, deafness, vestibular disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Abscess (renal), increased blood urea nitrogen, polyuria, pyelonephritis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Abnormal breath sounds, bronchospasm, cough, dyspnea, epistaxis, sinusitis, tonsillitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Psoriasis only:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Chest pain, flushing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness, insomnia, nervousness, pain, psychiatric disturbance, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Acne vulgaris, folliculitis, hyperkeratosis, pruritus, skin rash, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hot flash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal distention, constipation, gingival hemorrhage, increased appetite</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary frequency</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Abnormal erythrocytes, altered platelet function, blood coagulation disorder, carcinoma, hemorrhagic diathesis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Hyperbilirubinemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Bronchospasm, cough, dyspnea, flu-like symptoms, respiratory tract infection, rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Rare but important or life-threatening; any indication:</b> Anaphylaxis/anaphylactoid reaction (possibly associated with Cremophor EL vehicle in injection formulation), brain disease, central nervous system toxicity, cholestasis, cholesterol increased, exacerbation of psoriasis (transformation to erythrodermic or pustular psoriasis), gout, haemolytic uremic syndrome, hepatic insufficiency, hepatitis, hyperbilirubinemia, hyperkalemia, hyperlipidemia, hypertrichosis, hyperuricemia, hypomagnesemia, impaired consciousness, increased susceptibility to infection (including JC virus and BK virus), jaundice, leg pain (possibly a manifestation of Calcineurin-Inhibitor Induced Pain Syndrome), malignant lymphoma, migraine, myalgia, myopathy, myositis, papilledema, progressive multifocal leukoencephalopathy, pseudotumor cerebri, pulmonary edema (noncardiogenic), renal disease (polyoma virus-associated), reversible posterior leukoencephalopathy syndrome, rhabdomyolysis, thrombotic microangiopathy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012561\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to cyclosporine or any component of the formulation. IV cyclosporine is contraindicated in hypersensitivity to polyoxyethylated castor oil (Cremophor EL).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rheumatoid arthritis and psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies. Concomitant treatment with PUVA or UVB therapy, methotrexate, other immunosuppressive agents, coal tar, or radiation therapy are also contraindications for use in patients with psoriasis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Concurrent use with bosentan; rheumatoid arthritis and psoriasis patients with primary or secondary immunodeficiency excluding autoimmune disease, uncontrolled infection, or malignancy (excluding non-melanoma skin cancer).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012600\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gingival hyperplasia: Gingival hyperplasia may occur; avoid concomitant nifedipine in patients who develop gingival hyperplasia (may increase frequency of hyperplasia). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity: Hepatotoxicity (transaminase and bilirubin elevations) and liver injury (including cholestasis, jaundice, hepatitis, and liver failure) have been reported. These events were mainly in patients with confounding factors including infections, coadministration with other potentially hepatotoxic medications, underlying conditions, and significant comorbidities. Fatalities have also been reported rarely, primarily in transplant patients. Increased hepatic enzymes and bilirubin have occurred, usually in the first month and when used at high doses; improvement is usually seen with dosage reduction. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperkalemia: Significant hyperkalemia, with or without hyperchloremic metabolic acidosis, has been reported. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypertension:<b> [US Boxed Warning]: May cause hypertension; risk is increased with increasing doses/duration. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperuricemia: Significant hyperuricemia has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infections:<b> [US Boxed Warning]: Increased risk of infection with use; </b> fatal infections have been reported. Bacterial, viral, fungal, and protozoal infections (including opportunistic infections) have occurred. Polyoma virus infections, such as the JC virus and BK virus, may result in serious and sometimes fatal outcomes. The JC virus is associated with progressive multifocal leukoencephalopathy (PML), and PML has been reported in patients receiving cyclosporine. PML may be fatal and presents with hemiparesis, apathy, confusion, cognitive deficiencies, and ataxia; consider neurologic consultation as indicated. The BK virus is associated with nephropathy, and polyoma virus-associated nephropathy (PVAN) has been reported in patients receiving cyclosporine. PVAN is associated with serious adverse effects including renal dysfunction and renal graft loss. If PML or PVAN occur in transplant patients, consider reducing immunosuppression therapy as well as the risk  that reduced immunosuppression poses to grafts.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Malignancy:<b> [US Boxed Warning]: Increased risk of lymphomas and other malignancies</b> (including fatal outcomes), <b>particularly skin cancers;</b> risk is related to intensity/duration of therapy and the use of more than one immunosuppressive agent; all patients should avoid excessive sun/UV light exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nephrotoxicity: <b>[US Boxed Warning]: Renal impairment, including structural kidney damage has occurred (when used at high doses); risk is increased with increasing doses/duration; monitor renal function closely.</b> Use caution with other potentially nephrotoxic drugs (eg, acyclovir, aminoglycoside antibiotics, amphotericin B, ciprofloxacin); monitor renal function closely with concomitant use. If significant renal impairment occurs, reduce the dose of the coadministered medication or consider alternative treatment. Elevations in serum creatinine and BUN associated with nephrotoxicity generally respond to dosage reductions. In renal transplant patients with rapidly rising BUN and creatinine, carefully evaluate to differentiate between cyclosporine-associated nephrotoxicity and renal rejection episodes. In cases of severe rejection that fail to respond to pulse steroids and monoclonal antibodies, switching to an alternative immunosuppressant agent may be preferred to increasing cyclosporine to excessive blood concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: May cause seizures, particularly if used with high-dose corticosteroids. Encephalopathy (including posterior reversible encephalopathy syndrome [PRES]) has also been reported; predisposing factors include hypertension, hypomagnesemia, hypocholesterolemia, high-dose corticosteroids, high cyclosporine serum concentration, and graft-versus-host disease (GVHD). Encephalopathy may be more common in patients with liver transplant compared to kidney transplant. Other neurotoxic events, such as optic disc edema (including papilloedema and potential visual impairment), have been rarely reported primarily in transplant patients. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin cancer: <b>[US Boxed Warning]: Risk of skin cancer may be increased in psoriasis patients with a history of PUVA and possibly methotrexate or other immunosuppressants, UVB, coal tar, or radiation; </b> increased risk of skin cancer has also been established in transplant patients; risk is related to intensity/duration of therapy and the use of more than one immunosuppressive agent; all patients should avoid excessive sun/UV light exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thrombotic microangiopathy: In transplant patients, syndromes of microangiopathic hemolytic anemia and thrombocytopenia have occurred and may result in graft failure; it is accompanied by platelet consumption within the graft. Syndrome may occur without graft rejection. Although management of the syndrome is unclear, discontinuation or reduction of cyclosporine, in addition to streptokinase and heparin administration or plasmapheresis, has been associated with syndrome resolution. However, resolution seems to be dependent upon early detection of the syndrome via indium 111 labeled platelet scans.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Cyclosporine has extensive hepatic metabolism and exposure is increased in patients with severe hepatic impairment. May require dose reduction. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Psoriasis: Appropriate use: If receiving other immunosuppressive agents, radiation or UV therapy, concurrent use of cyclosporine is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cyclosporine combination therapy in renal transplant: Due to the increased risk for nephrotoxicity in renal transplantation, avoid using standard doses of cyclosporine in combination with everolimus; reduced cyclosporine doses are recommended; monitor cyclosporine concentrations closely. Cyclosporine and everolimus combination therapy may increase the risk for proteinuria. Cyclosporine combined with either everolimus or sirolimus may increase the risk for thrombotic microangiopathy/thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TMA/TTP/HUS).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug/drug-food interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Transplant patients: To be used initially with corticosteroids. Make dose adjustments based on cyclosporine blood concentrations. Anaphylaxis has been reported with IV use; reserve for patients who cannot take oral form.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Corn oil: Product may contain corn oil.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ethanol: Products may contain ethanol. The alcohol content should be considered in certain patient populations, including pregnant or breast-feeding women, patients with liver disease, seizure disorders, alcohol dependency, or pediatric patients. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Non-interchangeability of modified/non-modified forms: <b>[US Boxed Warning]: The modified/non-modified formulations are not bioequivalent; cyclosporine (modified) has increased bioavailability as compared to cyclosporine (non-modified) and the products cannot be used interchangeably without close monitoring.</b> Cyclosporine (modified) refers to the oral solution and capsule dosage formulations of cyclosporine in an aqueous dispersion (previously referred to as &ldquo;microemulsion&rdquo;).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Polyoxyethylated castor oil: Cyclosporine for injection contains the vehicle polyoxyethylated castor oil (Cremophor EL), which is associated with hypersensitivity (anaphylactic) reactions. Due to the risk for anaphylaxis, IV cyclosporine should be reserved for use in patients unable to take an oral formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced physician: <b>[US Boxed Warning]: Prescribing and dosage adjustment should only be under the direct supervision of an experienced physician. Adequate laboratory/medical resources and follow-up are necessary. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Monitoring of concentrations: Monitor cyclosporine concentrations closely following the addition, modification, or deletion of other medications.  <b>[US Boxed Warning]: Cyclosporine non-modified absorption is erratic; monitor blood concentrations closely. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vaccines: Live, attenuated vaccines may be less effective; vaccination should be avoided.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26523000\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012607\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BCRP/ABCG2, BSEP/ABCB11, CYP2C9 (weak), CYP3A4 (weak), OATP1B1/SLCO1B1, P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012608\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15960&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AcetaZOLAMIDE: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adalimumab: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: Per US labeling: reduce afatinib by 10mg if not tolerated.  Per Canadian labeling: avoid combination if possible; if used, administer the P-gp inhibitor simultaneously with or after the dose of afatinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: CycloSPORINE (Systemic) may increase the serum concentration of Aliskiren. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ambrisentan: CycloSPORINE (Systemic) may increase the serum concentration of Ambrisentan.  Management: Limit ambrisentan dose to 5 mg/day and monitor for ambrisentan adverse reactions in patients receiving systemic cyclosporine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May increase the serum concentration of CycloSPORINE (Systemic). Management: Monitor for increased serum concentrations and/or toxicity of cyclosporine if combined with amiodarone. A reduction in cyclosporine dosage will likely be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of CycloSPORINE (Systemic). Fluconazole and isavuconazonium considerations are addressed in separate monographs.<b> Exceptions: </b>Fluconazole; Isavuconazonium Sulfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Armodafinil: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ascorbic Acid: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: OATP1B1/SLCO1B1 Inhibitors may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: CycloSPORINE (Systemic) may increase the serum concentration of AtorvaSTATin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azithromycin (Systemic): May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May increase the metabolism of CycloSPORINE (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betrixaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Betrixaban.  Management: Decrease the betrixaban dose to an initial single dose of 80 mg followed by 40 mg once daily if combined with a P-glycoprotein inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine.  Management: Consider alternatives when possible; bilastine should be avoided in patients with moderate to severe renal insufficiency who are receiving p-glycoprotein inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: CycloSPORINE (Systemic) may increase the serum concentration of Boceprevir. Boceprevir may increase the serum concentration of CycloSPORINE (Systemic).  Management: Cyclosporine dose adjustments will likely be necessary when used together with boceprevir.  Monitor serum cyclosporine concentrations closely, and monitor patients for evidence of cyclosporine toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CycloSPORINE (Systemic) may increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Dihydropyridine): May increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).<b> Exceptions: </b>Clevidipine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Monitor frequently for decreased serum concentrations and therapeutic effects of cyclosporine if combined with carbamazepine. Increased cyclosporine doses will likely be needed to maintain adequate serum concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caspofungin: CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Caspofungin. CycloSPORINE (Systemic) may increase the serum concentration of Caspofungin.  Management: Weigh potential benefits of caspofungin against a possible elevated risk of hepatotoxicity.  Monitor liver function and re-evaluate treatment in patients with abnormal values.  Mild transaminase elevations may occur relatively commonly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): May increase the serum concentration of CycloSPORINE (Systemic). Management: Cyclosporine dose reductions will likely be required with initiation of concurrent chloramphenicol.  Monitor cyclosporine concentrations and response closely following initiation and/or discontinuation of chloramphenicol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholic Acid: BSEP/ABCB11 Inhibitors may decrease the excretion of Cholic Acid. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colesevelam: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Administer cyclosporine at least 4 hours prior to colesevelam.  Monitor for decreased cyclosporine concentrations during concomitant colesevelam therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Crizotinib: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: May enhance the immunosuppressive effect of CycloSPORINE (Systemic). Cyclophosphamide may decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Systemic): May decrease the serum concentration of CycloSPORINE (Systemic). Dexamethasone (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Dexamethasone (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: CycloSPORINE (Systemic) may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CycloSPORINE (Systemic) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Consider a doxorubicin dose reduction, as clinically appropriate, when used with cyclosporine. Use this combination with caution; increase monitoring for toxic effects of doxorubicin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May increase the serum concentration of CycloSPORINE (Systemic). Specifically, dronabinol may displace cyclosporine from its protein-binding sites, leading to an increased concentration of active, unbound drug.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: CycloSPORINE (Systemic) may increase the serum concentration of Dronedarone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban.  Management: See full monograph for details. Reduced doses are recommended for patients receiving edoxaban for venous thromboembolism in combination with certain inhibitors. Similar dose adjustment is not recommended for edoxaban use in atrial fibrillation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Increase monitoring of cyclosporine concentrations when starting, stopping, or adjusting doses of concurrent efavirenz, particularly within the first 2 weeks.  Cyclosporine dose adjustment may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: CycloSPORINE (Systemic) may decrease the serum concentration of Eltrombopag. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: CycloSPORINE (Systemic) may increase the serum concentration of Eluxadoline.  Management: Decrease the eluxadoline dose to 75 mg twice daily if combined with cyclosporine and monitor patients for increased eluxadoline effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: May enhance the hyperkalemic effect of CycloSPORINE (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Systemic): May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide: CycloSPORINE (Systemic) may decrease the metabolism of Etoposide.  Management: Consider reducing the dose of etoposide by 50% if the patient is receiving, or has recently received, cyclosporine. Monitor for increased toxic effects of etoposide if cyclosporine is initiated, the dose is increased, or it has been recently discontinued.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide Phosphate: CycloSPORINE (Systemic) may increase the serum concentration of Etoposide Phosphate. CycloSPORINE may decrease the metabolism, via CYP isoenzymes, and decrease the p-glycoprotein-mediated elimination of Etoposide Phosphate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: CycloSPORINE (Systemic) may increase the serum concentration of Everolimus.  Management: When using everolimus for renal cell carcinoma, avoid concurrent cyclosporine.  When using everolimus as post-transplant immunosuppression, concurrent cyclosporine should be used at lower doses and with lower target serum cyclosporine concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ezetimibe: May increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Ezetimibe.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fibric Acid Derivatives: CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Fibric Acid Derivatives. Fibric Acid Derivatives may decrease the serum concentration of CycloSPORINE (Systemic).  Management: Careful consideration of the risks and benefits should be undertaken prior to use of this combination; extra monitoring of renal function and cyclosporine concentrations will likely be required.  Adjustment of cyclosporine dose may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fimasartan: CycloSPORINE (Systemic) may increase the serum concentration of Fimasartan. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluvastatin: CycloSPORINE (Systemic) may increase the serum concentration of Fluvastatin.  Management: Limit fluvastatin to 20 mg twice daily in patients who are also receiving cyclosporine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glecaprevir and Pibrentasvir: CycloSPORINE (Systemic) may increase the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GlyBURIDE: CycloSPORINE (Systemic) may diminish the therapeutic effect of GlyBURIDE. GlyBURIDE may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May decrease the metabolism of CycloSPORINE (Systemic). Management: Monitor for altered cyclosporine concentrations/effects if grapefruit intake is increased/decreased.  Advise patients to not alter their pattern of grapefruit/grapefruit juice intake without consulting their healthcare provider.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grazoprevir: CycloSPORINE (Systemic) may increase the serum concentration of Grazoprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Griseofulvin: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: CycloSPORINE (Systemic) may increase the serum concentration of Ibrutinib.  Management: When treating B-cell malignancies, consider decreasing ibrutinib to 140 mg daily. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imipenem: CycloSPORINE (Systemic) may enhance the neurotoxic effect of Imipenem. Imipenem may decrease the serum concentration of CycloSPORINE (Systemic). Imipenem may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lercanidipine: May increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Lercanidipine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Letermovir: May increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Letermovir. Management: Decrease the letermovir dose to 240 mg daily when combined with cyclosporine. Additionally, monitor for increased cyclosporine concentrations and toxicities when combined with letermovir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lovastatin: CycloSPORINE (Systemic) may increase the serum concentration of Lovastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melphalan: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: CycloSPORINE (Systemic) may increase the serum concentration of Methotrexate. This may result in nausea, vomiting, oral ulcers, hepatotoxicity and/or nephrotoxicity. Methotrexate may increase the serum concentration of CycloSPORINE (Systemic). This may result in nephrotoxicity. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MethylPREDNISolone: CycloSPORINE (Systemic) may increase the serum concentration of MethylPREDNISolone. MethylPREDNISolone may increase the serum concentration of CycloSPORINE (Systemic). MethylPREDNISolone may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May increase the absorption of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metreleptin: May decrease the serum concentration of CycloSPORINE (Systemic). Metreleptin may increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mifamurtide: CycloSPORINE (Systemic) may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CycloSPORINE (Systemic). Management: Avoid cyclosporine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minoxidil (Systemic): CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Minoxidil (Systemic). Severe hypertrichosis has been reported. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minoxidil (Topical): CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Minoxidil (Topical). Specifically, hypertrichosis risk may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MitoXANTRONE: CycloSPORINE (Systemic) may increase the serum concentration of MitoXANTRONE.  Management: Consider mitoxantrone dose reduction, as clinically appropriate, when used with cyclosporine. Use this combination with caution and monitor closely for toxic effects of mitoxantrone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Modafinil: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: CycloSPORINE (Systemic) may decrease the serum concentration of Mycophenolate. Specifically, cyclosporine may decrease concentrations of the active metabolite mycophenolic acid.  Management: Mycophenolate requirements may be greater in patients receiving cyclosporine. Monitor mycophenolate dosing and response to therapy particularly closely when adjusting concurrent cyclosporine (starting, stopping, or changing dose).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nafcillin: May increase the metabolism of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: CycloSPORINE (Systemic) may increase the serum concentration of Neratinib.  Management: Avoid concomitant use of neratinib and cyclosporine if possible. If combined, monitor for increased neratinib effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: CycloSPORINE (Systemic) may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Norfloxacin: May decrease the metabolism of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: BSEP/ABCB11 Inhibitors may increase serum concentrations of the active metabolite(s) of Obeticholic Acid.  Management: Avoid concomitant use of obeticholic acid and bile salt efflux pump (BSEP) inhibitors if possible. If concomitant therapy is necessary, monitor patients for elevated liver transaminases and elevated bilirubin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, and Ritonavir: May increase the serum concentration of CycloSPORINE (Systemic). Management: Reduce cyclosporine dose by 80% when initiating therapy with ombitasvir/paritaprevir/ritonavir and monitor cyclosporine blood levels closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May increase the serum concentration of CycloSPORINE (Systemic). Management: Reduce cyclosporine dose 80% when initiating therapy with ombitasvir/paritaprevir/ritonavir/dasabuvir and monitor cyclosporine blood levels closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omeprazole: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Administer orlistat at least 3 hours before or after oral cyclosporine.  Monitor for decreased serum concentrations of oral cyclosporine, even with the recommended dose separation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: BCRP/ABCG2 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May increase the metabolism of CycloSPORINE (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitavastatin: CycloSPORINE (Systemic) may increase the serum concentration of Pitavastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of CycloSPORINE (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pravastatin: CycloSPORINE (Systemic) may increase the serum concentration of Pravastatin. Pravastatin may increase the serum concentration of CycloSPORINE (Systemic).  Management: Limit pravastatin to 20 mg/day in patients who are also receiving cyclosporine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PrednisoLONE (Systemic): May decrease the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of PrednisoLONE (Systemic). PrednisoLONE (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PredniSONE: CycloSPORINE (Systemic) may increase serum concentrations of the active metabolite(s) of PredniSONE. PredniSONE may decrease the serum concentration of CycloSPORINE (Systemic). PredniSONE may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Protease Inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pyrazinamide: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinupristin: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ranolazine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: CycloSPORINE (Systemic) may increase the serum concentration of Repaglinide.  Management: Limit the daily repaglinide dose to a maximum of 6 mg with concurrent use of cyclosporine, and monitor closely for increased repaglinide effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May increase the metabolism of CycloSPORINE (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAXIMin: CycloSPORINE (Systemic) may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of CycloSPORINE (Systemic). Management: Consider empiric cyclosporine dose reductions and monitor cyclosporine serum concentrations closely if ritonavir is initiated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosuvastatin: CycloSPORINE (Systemic) may increase the serum concentration of Rosuvastatin.  Management: Limit rosuvastatin to 5 mg/day in patients who are also receiving cyclosporine.  Canadian labeling contraindicates concomitant use of rosuvastatin with cyclosporine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sevelamer: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Simeprevir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: CycloSPORINE (Systemic) may increase the serum concentration of Simvastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: May enhance the adverse/toxic effect of CycloSPORINE (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described. CycloSPORINE (Systemic) may increase the serum concentration of Sirolimus. This is of specific concern with cyclosporine [MODIFIED]. Management: Administer oral doses of sirolimus 4 hours after doses of cyclosporine.  Monitor for toxic effects of sirolimus if used with cyclosporine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Somatostatin Analogs: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Consider alternatives to St. John's wort (SJW). If the combination cannot be avoided, monitor for decreased cyclosporine concentrations/effects.  Monitor for increased cyclosporine concentrations/effects following SJW discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfinpyrazone: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonamide Antibiotics: May enhance the nephrotoxic effect of CycloSPORINE (Systemic). Sulfonamide Antibiotics may decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Tacrolimus (Systemic). Tacrolimus (Systemic) may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Tacrolimus (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Tacrolimus (Topical). Tacrolimus (Topical) may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Tacrolimus (Topical) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of CycloSPORINE (Systemic). Management: Significant cyclosporine dose reductions are likely to be required if used with telaprevir. Concurrent use should be performed with great caution and close monitoring of both cyclosporine concentrations and clinical response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telithromycin: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: May enhance the adverse/toxic effect of CycloSPORINE (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described with concomitant sirolimus use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: CycloSPORINE (Systemic) may increase the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voxilaprevir: OATP1B1/SLCO1B1 Inhibitors may increase the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012612\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit juice increases cyclosporine serum concentrations. Management: Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012556\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012557\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed following the use of oral cyclosporine in animal reproduction studies (using doses that were not maternally toxic). In humans, cyclosporine crosses the placenta; maternal concentrations do not correlate with those found in the umbilical cord. Cyclosporine may be detected in the serum of newborns for several days after birth (Claris 1993). Based on clinical use, premature births and low birth weight were consistently observed in pregnant transplant patients (additional pregnancy complications also present). Formulations may contain alcohol; the alcohol content should be taken into consideration in pregnant women.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The pharmacokinetics of cyclosporine may be influenced by pregnancy (Grimer 2007). Cyclosporine may be used in pregnant renal, liver, or heart transplant patients (Cowan 2012; EBPG Expert Group on Renal Transplantation 2002; McGuire 2009; Parhar 2012). If therapy is needed for psoriasis, other agents are preferred; however, cyclosporine may be used as an alternative agent along with close clinical monitoring; use should be avoided during the first trimester if possible (Bae 2012). If treatment is needed for lupus nephritis, other agents are recommended to be used in pregnant women (Hahn 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Following transplant, normal menstruation and fertility may be restored within months; however, appropriate contraception is recommended to prevent pregnancy until 1-2 years following the transplant to improve pregnancy outcomes (Cowan 2012; EBPG Expert Group on Renal Transplantation 2002; McGuire 2009; Parhar 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10825784\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor plasma concentrations periodically and following the addition, modification, or deletion of other medications. Monitor renal function (serum creatinine and BUN) after any cyclosporine dosage changes or addition, modification, or deletion of other medications. Monitor blood pressure after any cyclosporine dosage changes or addition, modification, or deletion of other medications. Monitor for hypersensitivity reactions (IV cyclosporine). Monitor for signs/symptoms of hepatotoxicity, secondary malignancy, infection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transplant patients: Cyclosporine trough concentrations, serum electrolytes, renal function, hepatic function, blood pressure, lipid profile</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Psoriasis therapy: Baseline blood pressure, serum creatinine (2 levels each), BUN, CBC, serum magnesium, potassium, uric acid, lipid profile. Biweekly monitoring of blood pressure, complete blood count, serum creatinine, and levels of BUN, uric acid, potassium, lipids, and magnesium during the first 3 months of treatment for psoriasis. Monthly monitoring is recommended after this initial period. Also evaluate any atypical skin lesions prior to therapy. Increase the frequency of blood pressure monitoring after each alteration in dosage of cyclosporine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rheumatoid arthritis: Baseline blood pressure, and serum creatinine (2 levels each); serum creatinine every 2 weeks for first 3 months, then monthly if patient is stable. Increase the frequency of blood pressure monitoring after each alteration in dosage of cyclosporine. Additional Canadian labeling recommendations include CBC, hepatic function, urinalysis, serum potassium, and uric acid (baseline and periodic thereafter).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10825785\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reference ranges are method- and specimen-dependent; use the same analytical method consistently; trough concentrations should be obtained:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 12 to 18 hours after dose (chronic usage)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 12 hours after dose <b>or</b> immediately prior to next dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic concentrations: Not well-defined; dependent on organ transplanted, time after transplant, organ function, and cyclosporine toxicity; refer to institution specific protocols. General range: 100 to 400 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toxic concentration: Not well defined, nephrotoxicity may occur at any level.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012568\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibition of production and release of interleukin II and inhibits interleukin II-induced activation of resting T-lymphocytes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012571\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyclosporine (non-modified): Erratic and incomplete; dependent on presence of food, bile acids, and GI motility; larger oral doses are needed in pediatrics due to shorter bowel length and limited intestinal absorption</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyclosporine (modified): Erratic and incomplete; increased absorption, up to 30% when compared to cyclosporine (non-modified); less dependent on food, bile acids, or GI motility when compared to cyclosporine (non-modified)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely in tissues and body fluids including the liver, pancreas, and lungs</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>dss</sub>: 4-6 L/kg in renal, liver, and marrow transplant recipients (slightly lower values in cardiac transplant patients; children &lt;10 years have higher values); ESRD: 3.49 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 90% to 98% to lipoproteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic via CYP3A4; forms at least 25 metabolites; extensive first-pass effect following oral administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyclosporine (non-modified): Dependent on patient population and transplant type (&lt;10% in adult liver transplant patients and as high as 89% in renal transplant patients); bioavailability of Sandimmune capsules and oral solution are equivalent; bioavailability of oral solution is ~30% of the IV solution</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children: 28% (range: 17% to 42%); gut dysfunction common in BMT patients and oral bioavailability is further reduced</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyclosporine (modified): Bioavailability of Neoral capsules and oral solution are equivalent:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children: 43% (range: 30% to 68%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 23% greater than with cyclosporine (non-modified) in renal transplant patients; 50% greater in liver transplant patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Oral: May be prolonged in patients with hepatic impairment and shorter in pediatric patients due to the higher metabolism rate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyclosporine (non-modified): Biphasic: Alpha: 1.4 hours; Terminal: 19 hours (range: 10-27 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyclosporine (modified): Biphasic: Terminal: 8.4 hours (range: 5-18 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyclosporine (non-modified): 2-6 hours; some patients have a second peak at 5-6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyclosporine (modified): Renal transplant: 1.5-2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily feces; urine (6%, 0.1% as unchanged drug and metabolites); clearance is more rapid in pediatric patients than in adults</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012694\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (CycloSPORINE Modified Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $41.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $82.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $164.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (CycloSPORINE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $99.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $335.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Gengraf Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $63.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $126.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $251.87</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Neoral Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (1): $2.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $9.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (SandIMMUNE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (1): $4.27</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $16.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (CycloSPORINE Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (5 mL): $46.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (CycloSPORINE Modified Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (50 mL): $299.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gengraf Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (50 mL): $474.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Neoral Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (50 mL): $536.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (SandIMMUNE Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (5 mL): $65.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (SandIMMUNE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (50 mL): $820.09</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961966\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Arpimune (PH);</li>\n      <li>Biosporin (EC);</li>\n      <li>Capimune (GB);</li>\n      <li>Cermox (AR);</li>\n      <li>Ciclohexal (ZA);</li>\n      <li>Cicloral (AU, DE);</li>\n      <li>Cipol (KR);</li>\n      <li>Cipol-N (KR);</li>\n      <li>Ciqorin (ES);</li>\n      <li>Cloperin (BD);</li>\n      <li>Consupren (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Cyclonix (BD);</li>\n      <li>Cyclorine (JO);</li>\n      <li>Cyrin (PH);</li>\n      <li>Deximune (GB, IL, MT, SG);</li>\n      <li>Equoral (AE, EE, HR, LT, RO, TH);</li>\n      <li>Gengraf (AE, HK, MY, QA, SA, VN);</li>\n      <li>Ikervis (IE);</li>\n      <li>Implanta (KR);</li>\n      <li>Imusporin (CO, IN);</li>\n      <li>Imusporyn (UA);</li>\n      <li>Kasporin (TH);</li>\n      <li>Neoral (FR, GB, IE, JP, NZ, TW);</li>\n      <li>Osporin (PH);</li>\n      <li>Promune (LK);</li>\n      <li>Sandimmum Neoral (ES);</li>\n      <li>Sandimmun (AT, AU, BE, BF, BJ, CH, CI, CL, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, ID, IE, IL, IS, IT, JP, KE, KR, LR, LU, MA, ML, MR, MU, MW, MY, NE, NG, NO, NZ, PE, PH, PK, PL, PT, RU, SC, SD, SE, SI, SK, SL, SN, TN, TR, TW, TZ, UG, UY, VE, ZM, ZW);</li>\n      <li>Sandimmun Neoral (AE, AR, AT, AU, BH, BR, CH, CL, CU, CY, CZ, EE, EG, FI, GB, GR, HK, HR, ID, IL, IQ, IR, IS, JO, KR, KW, LB, LK, LT, LV, LY, MT, MY, NO, OM, PE, PH, PL, PY, QA, RO, SA, SE, SI, SK, SY, TH, TR, UA, UY, VE, VN, YE, ZA);</li>\n      <li>Sandimmune (BB, NL);</li>\n      <li>Sigamsporin (AE);</li>\n      <li>Sigmasporin (KW, QA);</li>\n      <li>Sporium (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    al-Uzri A, Conley SB, Orlandi P, So S, Salvatierra O Jr. Aggressive early cyclosporine therapy is desirable in pediatric renal transplantation. <i>Transplant Proc</i>. 1994;26(1):88-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/8109036/pubmed\" target=\"_blank\" id=\"8109036\">8109036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alvarez F, Atkison PR, Grant DR, et al. NOF-11: a one-year pediatric randomized double-blind comparison of neoral versussandimmune in orthotopic liver transplantation. <i>Transplantation</i>. 2000;69(1):87-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/10653385/pubmed\" target=\"_blank\" id=\"10653385\">10653385</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alvarez F, Ciocca M, Ca&ntilde;ero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. <i>J Hepatol</i>. 1999;30(2):222-227.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/10068099/pubmed\" target=\"_blank\" id=\"10068099\">10068099</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aragon E, Chan YH, Ng KH, Lau YW, Tan PH, Yap HK. Good outcomes with mycophenolate-cyclosporine-based induction protocol in children withsevere proliferative lupus nephritis. <i>Lupus</i>. 2010;19(8):965-973.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/20581019/pubmed\" target=\"_blank\" id=\"20581019\">20581019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bae YS, Van Voorhees AS, Hsu S, et al. National Psoriasis Foundation. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. <i>J Am Acad Dermatol</i>. 2012;67(3):459-477.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/22018758/pubmed\" target=\"_blank\" id=\"22018758\">22018758</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benfield MR, Tejani A, Harmon WE, et al. A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation. <i>Pediatr Transplant</i>. 2005;9(3):282-292.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/15910382/pubmed\" target=\"_blank\" id=\"15910382\">15910382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burckart GJ, Canafax DM, and Yee GC, &quot;Cyclosporine Monitoring,&quot; <i>Drug Intell Clin Pharm</i>, 1986, 20(9):649-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/3530679/pubmed\" target=\"_blank\" id=\"3530679\">3530679</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burckart GJ, Venkataramanan R, Ptachcinski RJ, et al. Cyclosporine absorption following orthotopic liver transplantation. <i>J Clin Pharmacol</i>.1986b;26(8):647-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/3540030/pubmed\" target=\"_blank\" id=\"3540030\">3540030</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burckart G, Starzl T, Williams L, et al. Cyclosporine monitoring and pharmacokinetics in pediatrie liver transplant patients. <i>Transplant Proc</i>. 1985;17(1):1172-1175.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/20640180/pubmed\" target=\"_blank\" id=\"20640180\">20640180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. <i>Am J Kidney Dis</i>. 2009;53(5):760-769.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/19268410/pubmed\" target=\"_blank\" id=\"19268410\">19268410</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clardy CW, Schroeder TJ, Myre SA, et al. Clinical variability of cyclosporine pharmacokinetics in adult and pediatric patients after renal, cardiac,hepatic, and bone-marrow transplants. <i>Clin Chem</i>. 1988;34(10):2012-2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/3048779/pubmed\" target=\"_blank\" id=\"3048779\">3048779</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Claris O, Picaud JC, Brazier JL, et al, &quot;Pharmacokinetics of Cyclosporin A in 16 Newborn Infants of Renal or Cardiac Transplant Mothers,&quot; <i>Dev Pharmacol Ther</i>, 1993, 20(3-4):180-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/7828451/pubmed\" target=\"_blank\" id=\"7828451\">7828451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cowan SW, Davison JM, Doria C, et al. Pregnancy after cardiac transplantation. <i>Cardiol Clin</i>. 2012;30(3):441-452.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/22813369/pubmed\" target=\"_blank\" id=\"22813369\">22813369</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cuarterolo M, Ciocca M, Velasco CC, et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. <i>J Pediatr Gastroenterol Nutr</i>. 2006;43(5):635-639.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/17130741/pubmed\" target=\"_blank\" id=\"17130741\">17130741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Debray D, Maggiore G, Girardet JP, Mallet E, Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. <i>J Pediatr</i>. 1999;135(1):111-114.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/10393616/pubmed\" target=\"_blank\" id=\"10393616\">10393616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    European Association for the Study of the Liver(EASL). EASL Clinical Practice Guidelines: Autoimmune hepatitis. <i>J Hepatol</i>. 2015;63(4):971-1004.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/26341719/pubmed\" target=\"_blank\" id=\"26341719\">26341719</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. <i>Nephrol Dial Transplant</i>. 2002;(17 Suppl 4):50-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/12091650/pubmed\" target=\"_blank\" id=\"12091650\">12091650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Franulovi&#263; OZ, Rajaci&#263; N, Lesar T, Kuna AT, Mori&#263; BV. Cyclosporine induced biochemical remission in childhood autoimmune hepatitis. <i>Coll Antropol</i>. 2012;36(3):973-979.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/23213960/pubmed\" target=\"_blank\" id=\"23213960\">23213960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fu LW, Yang LY, Chen WP, Lin CY. Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis withheavy proteinuria. <i>Br J Rheumatol</i>. 1998;37(2):217-221.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/9569080/pubmed\" target=\"_blank\" id=\"9569080\">9569080</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gellermann J, Weber L, Pape L, et al. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. <i>J Am Soc Nephrol</i>. 2013;24(10):1689-1697.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/23813218/pubmed\" target=\"_blank\" id=\"23813218\">23813218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gengraf capsules (cyclosporine) [prescribing information]. North Chicago, IL: AbbVie Inc; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. <i>Pediatrics</i>. 2009;124(2):747-757.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/19651590/pubmed\" target=\"_blank\" id=\"19651590\">19651590</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grimer M; Caring for Australians with Renal Impairment (CARI). The CARI guidelines. Calcineurin inhibitors in renal transplantation: pregnancy, lactation and calcineurin inhibitors. <i>Nephrology (Carlton)</i>. 2007;(12 Suppl 1):S98-S105.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/17316288/pubmed\" target=\"_blank\" id=\"17316288\">17316288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hahn BH, McMahon MA, Wilkinson A, et al, &quot;American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis,&quot; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(6):797-808.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/22556106/pubmed\" target=\"_blank\" id=\"22556106\">22556106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hardinger KL, Koch MJ, and Brennan DC, &quot;Current and Future Immunosuppressive Strategies in Renal Transplantation,&quot; <i>Pharmacotherapy</i>, 2004, 24(9):1159-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/15460177/pubmed\" target=\"_blank\" id=\"15460177\">15460177</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holt DW, Mueller EA, Kovarik JM, et al, &quot;Sandimmune&reg; Neoral&reg; Pharmacokinetics: Impact of the New Oral Formulation,&quot; <i>Transplant Proc</i>, 1995, 27(1):1434-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/7878935/pubmed\" target=\"_blank\" id=\"7878935\">7878935</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kahan BD, Conley S, Portman R, et al. Parent-to-child transplantation with cyclosporine immunosuppression. <i>J Pediatr</i>.1987;111(6 Pt 2):1012-1016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/3316572/pubmed\" target=\"_blank\" id=\"3316572\">3316572</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kawasaki Y, Hosoya M, Takano K, et al. Efficacy of cyclosporine therapy for systemic lupus erythematosus in childhood. <i>Pediatr Int</i>. 2008;50(2):257-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/18353074/pubmed\" target=\"_blank\" id=\"18353074\">18353074</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. <i>Kidney inter., Suppl.</i> 2012; 139-274.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients.<i> American Journal of Transplantation </i>2009; 9(Suppl 3): S1&ndash;S157.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19450759\"></a>Lanino E, Rondelli R, Locatelli F, et al. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study. <i>Biol Blood Marrow Transplant</i>. 2009;15(6):741-748.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lin CY and Lee SF, &quot;Comparison of Pharmacokinetics Between CsA Capsules and Sandimmune&reg; Neoral&reg; in Pediatric Patients,&quot; <i>Transplant Proc</i>, 1994, 26(5):2973-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/7940938/pubmed\" target=\"_blank\" id=\"7940938\">7940938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Locatelli F, Zecca M, Rondelli R, et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. <i>Blood</i>. 2000;95(5):1572-1579.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/10688810/pubmed\" target=\"_blank\" id=\"10688810\">10688810</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. <i>Hepatology</i>. 2010;51(6):2193-2213.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/20513004/pubmed\" target=\"_blank\" id=\"20513004\">20513004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin P, Bleyzac N, Souillet G, et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatricbone marrow transplantation from matched-sibling or unrelated donors. <i>Bone Marrow Transplant</i>. 2003;32(9):881-887.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/14561988/pubmed\" target=\"_blank\" id=\"14561988\">14561988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McDiarmid SV, Busuttil RW, Ascher NL, et al. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial. <i>Transplantation</i>. 1995;59(4):530-536.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/7533345/pubmed\" target=\"_blank\" id=\"7533345\">7533345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGuire BM, Rosenthal P, Brown CC, et al; American Society of Transplantation. Long-term management of the liver transplant patient: recommendations for the primary care doctor. <i>Am J Transplant</i>. 2009;9(9):1988-2003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/19563332/pubmed\" target=\"_blank\" id=\"19563332\">19563332</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine forprophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. <i>Blood</i>. 2000;96(6):2062-2068.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/10979948/pubmed\" target=\"_blank\" id=\"10979948\">10979948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neoral (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis; March 2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/10979948/pubmed\" target=\"_blank\" id=\"10979948\">10979948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Niese D, &quot;A Double-Blind Randomized Study of Sandimmune&reg; Neoral&reg; vs Sandimmune&reg; in New Renal Transplant Recipients: Results After 12 Months,&quot; <i>Transplant Proc</i>, 1995, 27(2):1849-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/7725531/pubmed\" target=\"_blank\" id=\"7725531\">7725531</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parhar KS, Gibson PS, Coffin CS. Pregnancy following liver transplantation: review of outcomes and recommendations for management. <i>Can J Gastroenterol</i>. 2012;26(9):621-626.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/22993734/pubmed\" target=\"_blank\" id=\"22993734\">22993734</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plank C, Kalb V, Hinkes B, et al. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft f&uuml;r P&auml;diatrische Nephrologie. <i>Pediatr Nephrol</i>. 2008;23(9):1483-1493.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/18481113/pubmed\" target=\"_blank\" id=\"18481113\">18481113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandimmune (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sciveres M, Caprai S, Palla G, Ughi C, Maggiore G. Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents. <i>Aliment Pharmacol Ther</i>. 2004;19(2):209-217.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/14723612/pubmed\" target=\"_blank\" id=\"14723612\">14723612</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acutegraft versus host disease after marrow transplantation for leukemia. <i>N Engl J Med</i>. 1986;314(12):729-735.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/3513012/pubmed\" target=\"_blank\" id=\"3513012\">3513012</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suzuki K, Tanaka H, Tsugawa K, Ito E. Effective treatment with cyclosporine A of a child with systemic lupus erythematosus resistantto cyclophosphamide pulse therapy. <i>Tohoku J Exp Med</i>. 2006;208(4):355-359.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/16565599/pubmed\" target=\"_blank\" id=\"16565599\">16565599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suzuki H, Terai M, Hamada H, et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. <i>Pediatr Infect Dis J</i>. 2011;30(10):871-876.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/21587094/pubmed\" target=\"_blank\" id=\"21587094\">21587094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taesch S, Niese D, and Mueller EA, &quot;Sandimmune&reg; Neoral&reg;, A New Oral Formulation of Cyclosporine With Improved Pharmacokinetic Characteristics: Safety and Tolerability in Renal Transplant Patients,&quot; <i>Transplant Proc</i>, 1994, 26(6):3147-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/7998097/pubmed\" target=\"_blank\" id=\"7998097\">7998097</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tremoulet AH, Pancoast P, Franco A, et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. <i>J Pediatr</i>. 2012;161(3):506-512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/22484354/pubmed\" target=\"_blank\" id=\"22484354\">22484354</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tzakis AG, Reyes J, Todo S, et al. FK 506 versus cyclosporine in pediatric liver transplantation. <i>Transplant Proc</i>. 1991;23(6):3010-3015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/1721343/pubmed\" target=\"_blank\" id=\"1721343\">1721343</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wandstrat TL, Schroeder TJ, and Myre SA, &quot;Cyclosporine Pharmacokinetics in Pediatric Transplant Recipients,&quot; <i>Ther Drug Monit</i>, 1989, 11(5):493-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/2683250/pubmed\" target=\"_blank\" id=\"2683250\">2683250</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yee GC, &quot;Recent Advances in Cyclosporine Pharmacokinetics,&quot; <i>Pharmacotherapy</i>, 1991, 11(5):130S-134S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/1745619/pubmed\" target=\"_blank\" id=\"1745619\">1745619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15960 Version 212.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8012536\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8012539\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8012540\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10825673\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10825602\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8012692\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8012552\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21664250\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10825603\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130962\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8012616\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10825674\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8012538\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8012604\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8012561\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8012600\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26523000\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8012607\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8012608\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F8012612\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8012556\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8012557\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10825784\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F10825785\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8012568\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8012571\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8012694\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961966\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15960|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cyclosporine-ciclosporin-systemic-drug-information\" class=\"drug drug_general\">Cyclosporine (ciclosporin) (systemic): Drug information</a></li><li><a href=\"topic.htm?path=cyclosporine-ciclosporin-systemic-patient-drug-information\" class=\"drug drug_patient\">Cyclosporine (ciclosporin) (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}